---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010191"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:00:13.066111+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained

## Summary
- Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.
- OLE trial: pooled PANSS total score decreased 18.6 points (p≤0.0001) at 1 year; well tolerated with no single side effect >5%.
- Registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia expected to initiate mid-2025.
- Full OLE data including vocal and blood biomarkers due Q2 2025; NDA submission targeted Q4 2026.
- Completed public follow-on offering with gross proceeds of ~$18.0M in December 2024.

## SEC filing metadata
- accession: 0001437749-25-010191
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/0001437749-25-010191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/rvph20250325_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010191
- JSON: https://secwatch.observer/filing/0001437749-25-010191.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.